Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Leibl

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
The Journal of Investigative Dermatology|February 1, 1985
Expression of the Ly-5 alloantigenic system on epidermal cellsH Leibl, J Hutterer, H Korschan, et al.
Clinical and Experimental Immunology|September 11, 2016
Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficienciesM Borte, G Kriván, B Derfalvi, et al.
Vox Sanguinis|April 26, 2006
Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemiaJ Björkander, J Nikoskelainen, H Leibl, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
The Journal of Investigative Dermatology|February 1, 1985
Expression of the Ly-5 alloantigenic system on epidermal cellsH Leibl, J Hutterer, H Korschan, et al.
Clinical and Experimental Immunology|September 11, 2016
Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficienciesM Borte, G Kriván, B Derfalvi, et al.
Vox Sanguinis|April 26, 2006
Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemiaJ Björkander, J Nikoskelainen, H Leibl, et al.
Pageof 4